Filing Details

Accession Number:
0001562180-20-000489
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-22 21:20:02
Reporting Period:
2020-01-17
Accepted Time:
2020-01-22 21:20:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1603756 Axonics Modulation Technologies Inc. AXNX Surgical & Medical Instruments & Apparatus (3841) 454744083
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1756321 Fcpr 4 Biodiscovery 374 Rue Saint St Honore St.
75001 Paris
No No No No
1757283 Partners Andera 374 Rue Saint St Honore St.
75001 Paris
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-01-17 164,739 $31.51 3,092,722 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-22 135,261 $31.54 2,957,461 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $31.50 to $31.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. 2,224,128 shares are held of record by BioDiscovery 4 FCPR ("BioDiscovery") and 733,333 shares are held of record by BioDiscovery 5 ("BioDiscovery 5"). Andera Partners ("Andera") is the manager of BioDiscovery and BioDiscovery 5 and may be deemed to have sole voting and dispositive power over the shares held by BioDiscovery and BioDiscovery 5.
  3. This transaction was executed in multiple trades at prices ranging from $31.50 to $32.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.